ArticleCurrent oncology (Toronto, Ont.)2022

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.

Graeme Ball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.